KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. Matsumura T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, Wang CQ, Tokunaga K, Tirado-Magallanes R, Sian S, Benoukraf T, Okuda T, Asou N, Matsuoka M, Osato M, Suda T

    Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.

    Blood 136(17):1919-1932,2020. doi: 10.1182/blood.2019004292.

    https://pubmed.ncbi.nlm.nih.gov/32573733/

     

  2. Yasunaga JI.

    Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection: Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma.

    Front Microbiol 19;11:979,2020. 5.19 doi: 10.3389/fmicb.2020.00979.

    https://pubmed.ncbi.nlm.nih.gov/32508789/

     

  3. Matsumura T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, Wang CO, Tokunaga K,Tirado-Magallanes R, Sian S, Benoukraf T, Okuda T, Asou N, Matsuoka M, Osato M, Suda T.

    Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.

    Blood 136:1919-1932,2020. doi: 10.1182/blood.2019004292.

    https://pubmed.ncbi.nlm.nih.gov/32573733/

     

  4. Kuriyama H, Fukushima S, Nakahara S, Kanemaru H, Miyashita A, Aoi J, Tomita Y, Kawasaki T, Nosaka K and Ihn H.

    Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.

    J Dermatol 47(6):e235-e237,2020. doi: 10.1111/1346-8138.15336. Epub 2020 Apr 10.

    https://pubmed.ncbi.nlm.nih.gov/32275077/

     

  5. Hosokawa K, Ishiyama K, Ikemoto T, Sugimori C, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Nguyen MAT, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura J, Kanakura Y, Nakao S.

    The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure.

    Ann Hematol Online ahead of print,2020. doi: 10.1007/s00277-020-04314-w

    https://pubmed.ncbi.nlm.nih.gov/33095337/

     

  6. Makita S, Maruyama D, Maeshima AM, Taniguchi H, Yuda S, Toyoda K, Yamauchi N, Fukuhara S, Munakata W, Kobayashi Y, Kurihara H, Izutsu K and Tobinai K.

    A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

    Asia Pac J Clin Oncol 16(3):108-114,2020.  doi: 10.1111/ajco.13248. Epub 2019 Dec 4.

    https://pubmed.ncbi.nlm.nih.gov/31802636/

     

  7. Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, Imaizumi Y, Yoshimitsu M, Nosaka K, Ohtsuka E, Hidaka M, Jo T. Sasaki H, Moriuchi Y, Ogata M, Tatetsu H, Ishitsuka K, Miyazaki Y, Ueda R, Utsunomiya A, Ishida T.

    Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

    Blood A dv 4(20):5133-5145,2020. doi: 10.1182/bloodadvances. 2020003053.

    https://pubmed.ncbi.nlm.nih.gov/33091125/

     

  8. Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K.

    New Target investigators. Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.

    Int J Hematol 111 (6): 812-825,2020. doi: 10.1007/s12185-020-02843-8. Epub 2020 Mar 9.

    https://pubmed.ncbi.nlm.nih.gov/32152876/

     

  9. Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, Imaizumi Y, Yoshimitsu M, Nosaka K, Ohtsuka E, Hidaka M, Jo T. Sasaki H, Moriuchi Y, Ogata M, Tatetsu H, Ishitsuka K, Miyazaki Y, Ueda R, Utsunomiya A, Ishida T.

    Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

    Blood A dv 4(20):5133-5145,2020. doi: 10.1182/bloodadvances.2020003053.

    https://pubmed.ncbi.nlm.nih.gov/33091125/

     

  10. Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, Matsuoka M.

    HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

    Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749. doi: 10.1073/pnas.1922884117. Epub 2020 May 29.

    https://pubmed.ncbi.nlm.nih.gov/32471947/

     

     

  11. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K and Tsukasaki K for collaborative Investigators.

    Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.

    Cancer Sci 111(12): 4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21.

    https://pubmed.ncbi.nlm.nih.gov/32976684/

     

  12. Murata M, Yasunaga JI, Washizaki A, Seki Y, Kuramitsu M, Tan WK, Hu A, Okuma K, Hamaguchi I, Mizukami T, Matsuoka M, Araki H

    Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques.

    Retrovirology 17(1):15,2020. doi: 10.1186/s12977-020-00525-1.

    https://pubmed.ncbi.nlm.nih.gov/32576215/

     

  13. Kimura Y, Iwanaga E, Iwanaga K, Endo S, Inoue Y, Tokunaga K, Nagahata Y, Masuda K, Kawamoto H, Matsuoka M.

    A regulatory element in the 3′-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.

    Eur J Haematol. 2020 Nov 16.doi:10.1111/ejh.13551. PMID:33197296

    https://pubmed.ncbi.nlm.nih.gov/33197296/

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.